LIPAGLYN - The world’s first drug for treating diabetic dyslipidemiacombines lipid and glucose lowering effects in one single molecule.
About Diabetic Dyslipidemia
Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of the total cholesterol
Lipaglyn™ is the first Glitazar to be approved in the world and is the first NCE discovered and developed indigenously by an Indian Pharma Company.
How it Works?
Lipaglyn™ is a first-in-class drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in type 2 diabetes